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Nosocomial influenza is a large burden in hospi-
tals. Despite recommendations from the World 
Health Organization to vaccinate healthcare work-
ers against influenza, vaccine uptake remains low in 
most European countries. We performed a pragmatic 
cluster randomised controlled trial in order to assess 
the effects of implementing a multi-faceted influenza 
immunisation programme on vaccine coverage in hos-
pital healthcare workers (HCWs) and on in-patient mor-
bidity. We included hospital HCWs of three intervention 
and three control University Medical Centers (UMCs), 
and 3,367 patients. An implementation programme 
was offered to the intervention UMCs to assess the 
effects on both vaccine uptake among hospital staff 
and patient morbidity. In 2009/10, the coverage of 
seasonal, the first and second dose of pandemic influ-
enza vaccine as well as seasonal vaccine in 2010/11 
was higher in intervention UMCs than control UMCs 
(all p<0.05). At the internal medicine departments of 
the intervention group with higher vaccine coverage 
compared to the control group, nosocomial influenza 
and/or pneumonia was recorded in 3.9% and 9.7% of 
patients of intervention and control UMCs, respec-
tively (p=0.015). Though potential bias could not be 
completely ruled out, an increase in vaccine coverage 
was associated with decreased patient in-hospital 
morbidity from influenza and/or pneumonia.
Introduction 
The value of vaccinating healthcare workers (HCWs) 
against influenza has been subject of debate over 
decades. In the United States (US), despite respective 
immunisation recommendations since 1981, vaccine 
coverage among HCWs was only 63.5% in 2010-/11 
[1]. In the United Kingdom (UK), the Netherlands and 
other European countries, coverage is even lower [2,3]. 
Several arguments support influenza vaccination of 
HCWs. First, each year, influenza causes substantial 
morbidity and mortality among vulnerable patients 
in hospitals and nursing homes [4-6]. Since contacts 
between patients, visitors and HCWs are frequent in 
such settings, and HCWs who are infected with mild 
symptoms often continue to work [7], epidemics can 
easily develop and can be large [8]. Second, prophy-
laxis with neuraminidase inhibitors can be effective, 
but viral resistance may develop rendering these 
drugs less effective during influenza infections and 
such a strategy has not been routinely implemented in 
healthcare settings. Third, immunisation with the inac-
tivated influenza vaccine has been shown in a large 
meta-analysis of randomised controlled trials among 
healthy adults representative of the HCWs population 
to be 59% effective in preventing laboratory-confirmed 
influenza infection [9]. Fourth, a mathematical model 
for a 30-bed hospital predicted that seven HCWs need 
to be vaccinated to prevent one influenza infection in 
a patient [10]. Finally, despite some methodological 
constraints, a meta-analysis of four large randomised 
controlled trials in long-term care institutions showed 
significant reductions in patients presenting influenza-
like illness and patient mortality in settings with high 
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vaccine coverage among HCWs versus control settings 
with low coverage [11]. 
In the Netherlands, a high influenza vaccine uptake 
is reached among those belonging to risk groups for 
influenza. Each year, in October/November, general 
practitioners immunise patients aged 60 years or older 
and patients with risk-elevating diseases with stable 
high vaccination uptake rates above 71% across most 
parts of the Netherlands [12]. However, if younger than 
60 years and admitted for the first time with a high-risk 
diagnosis, patients are mostly not immunised since 
they did not belong to a risk group before. Also they 
are infrequently vaccinated in the hospital since there 
is no vaccination programme for hospitalised patients 
in the Netherlands.  
In contrast, in both the Netherlands and most other 
European countries, vaccine uptake among HCWs 
remains low and influenza vaccination programmes 
have been voluntary. To be effective in reaching high 
vaccine coverage against influenza, a large variety of 
behavioural and organisational factors has to be tar-
geted [13] and a setting- and culture- specific quan-
titative need assessment is essential to focus the 
programme on the most influential factors [14].
We applied the Intervention Mapping (IM) method [15] 
to structure the development of an influenza vaccina-
tion programme targeted at hospital staff. We here 
report the results of an evaluation of this programme. 
In the study, University Medical Centers (UMCs) from 
the Netherlands participated during the 2009/10 and 
2010/11 influenza seasons. We primarily set out to 
determine the effects of the programme on vaccine 
coverage among HCWs using a pragmatic cluster ran-
domised controlled trial. As clinical assessments from 
hospital settings are lacking, we also set out to deter-
mine the effects on patient outcomes during the stud-
ied influenza seasons.         
Methods
Design, setting and participants
We aimed to assess the clustered effects of a multi-
faceted influenza vaccination programme on influenza 
vaccine coverage in HCWs as well as the effect on 
influenza morbidity in hospitalised patients in UMCs 
in the Netherlands. In our trial, a cluster is the unit of 
randomisation defined as one UMC. In this study, we 
consider HCWs to be all employees working in the hos-
pital. The study period included the influenza seasons 
2009/10 and 2010/11. 
To reach the objectives we conducted a pragmatic clus-
ter randomised trial because the developed influenza 
vaccine implementation programme was best applied 
at hospital level rather than at individual level. All eight 
UMCs (Erasmus Medical Center, Rotterdam; Academic 
Medical Center, Amsterdam; University Medical 
Center, Groningen; University Medical Center, Utrecht; 
University Medical Center, Maastricht; Free University 
Medical Center, Amsterdam; University Medical Center, 
Nijmegen; Leiden University Medical Center, Leiden) 
were invited to participate in the trial. After permis-
sion from the Dutch Federation of UMCs, the board of 
directors of six of the eight UMCs agreed to randomisa-
tion at cluster level. The board of directors of the two 
remaining UMCs refused to be randomised because 
their institutions had already undertaken consider-
able efforts to raise influenza vaccine coverage among 
staff, but they agreed to act as external controls. 
Unfortunately, the two UMCs did not give permission 
to collect patient data.
At baseline, policies for the randomised UMCs were 
either to offer influenza vaccination to selected health-
care workers or not to vaccinate at all, and the high-
est vaccine coverage in any UMC was estimated at just 
below 27%. The baseline vaccine coverage in the exter-
nal UMCs was somewhat higher reaching levels as high 
as estimated at 37%, and there was more experience 
with immunistion campaigns. 
UMCs are tertiary referral centers each taking care of 
special hospitalised patient populations in the eight 
geographical regions of the Netherlands where they 
are placed. Acute care is delivered for a large num-
ber of patients who are admitted for a wide variety of 
indications. 
In May 2009, prior to the upcoming 2009/10 influenza 
season, six UMCs were randomly allocated by com-
puter (using the procedure Random in SPSS version 
18.0) into two clusters, either the intervention or the 
control group, by a researcher blinded to the identity of 
the UMCs. Since the UMCs were about similar in size, 
number of HCWs and annual number of hospitalisa-
tions, we did not match before randomisation. Since 
we conducted a pragmatic study, the outcome of ran-
domisation was neither blinded for the research group 
nor for the lead contacts of the UMCs. Although most 
HCWs were aware that they were targeted for vaccina-
tion, they did not know to which arm their UMC was 
randomly allocated. The study period covered the 
period from the first influenza vaccination campaign 
in September/October 2009 to the end of the influenza 
season 2010/11. The protocol of the trial was waived by 
the medical ethical committee of the University Medical 
Center Groningen for ethical approval according to the 
Dutch Law of Research with Humans (No. 2009.267). 
The study was conducted in accordance with the 
Dutch Law for the Protection of Personal Data (Wet 
Bescherming Persoonsgegevens) and the Declaration 
of Helsinki [16].  
Intervention
 In November and December 2008, prior to the trial start 
in 2009, we conducted a survey to assess which behav-
ioural and organisational factors were associated with 
vaccine uptake among hospital staff of the UMCs [17]. 
An 11-item prediction model with nine behavioural and 
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two demographic predictors could be developed that 
was highly accurate in discriminating vaccinated from 
non-vaccinated staff in approximately 95% of the study 
population. Subsequently, we used the Intervention 
Mapping (IM) method to thoroughly plan, develop and 
evaluate a programme that was directed at HCWs in 
order to influence their behaviour towards immunisa-
tion [15,18]. This IM method is a theoretical framework 
to systematically develop health education interven-
tions and can be used as part of the dynamic process 
of planning intervention strategies in health education. 
It contains six consecutive steps: (i) a needs assess-
ment, (ii) creating a matrix of proximal programme 
objectives, (iii) selecting theory-based intervention 
methods and practical strategies, (iv) programme plan-
ning, (v) adopting and implementing the programme, 
and (vi) monitoring and programme evaluation. 
Various educational tools were developed following 
the proximal objectives based on the needs assess-
ment (Box). Prior to the immunisation campaign in 
September 2009 and 2010, the programme educational 
tools were offered to the lead contact persons from 
the departments of occupational health of each UMC 
in the intervention and external group. These depart-
ments, in close collaboration with the communication 
units, are responsible for the influenza vaccination 
campaign. Information on the methods was provided 
to them by communication experts within the research 
group and they were encouraged to communicate the 
methods at various levels including the board of direc-
tors, heads of departments and staff members. The 
intervention and external group were allowed to make 
their own choices and decisions regarding the imple-
mentation of programme elements. An evaluation of 
the process showed that intervention and external 
UMCs targeted most of the behavioural determinants 
and choose to implement a variety of the developed 
methods, whereas the control UMCs targeted less 
determinants [18], Figure. However, actual exposure 
of HCWs to these methods was variable and in 2009 
largely affected by the pandemic preparedness plans. 
Lead contacts from the control group did not receive 
the developed methods and were encouraged to fol-
low their usual influenza vaccination policy. We did not 
seek to influence vaccine coverage among patients. 
Outcomes
The primary outcome measure of this trial was the 
influenza vaccine uptake among all HCWs at UMC level. 
Vaccine uptake was expressed as percentage calcu-
lated through dividing the number of all vaccinated 
HCWs by the total number of HCWs multiplied by 100. 
For financial administrative reasons all immunisations 
are accurately recorded at the hospital level, hence this 
information was regarded most valid. 
Secondary outcome measures were absenteeism rates 
among HCWs during December of each study year as 
this is normally the month in which influenza circulates 
at epidemic levels [19]. The cumulative absenteeism 
Box
Behavioural determinants associated with vaccine uptake 
and developed health education methods to increase 
influenza vaccine uptake, the Netherlands, 2009
Behavioural 
determinants Developed health education methods
Awareness of 
personal risk 
for influenza 
infection
•	 Provision of information on influenza, 
transmission and risks through an 
information stand at the UMC restaurants, a 
website, a folder and plenary meetings
•	 Polls and a quiz on the intranet
•	 Video testimonials with role models
Awareness 
of risk of 
infecting 
patients
•	 Provision of information on influenza and the 
risk of transmission to patients through an 
information stand at the UMC restaurants, a 
website, a folder and plenary meetings
•	 Polls and a quiz on the intranet
•	 Video testimonials with role models
Belief that 
vaccination 
reduces 
the risk of 
infecting 
patients
•	 Provision of information on influenza and 
the effectiveness of vaccination through an 
information stand at the UMC restaurants, a 
website, a folder and plenary meetings
•	 Polls and a quiz on the intranet
•	 Video testimonials with role models
Usefulness of 
vaccination 
despite the 
constant flow 
of visitors
•	 Provision of information on influenza and 
the effectiveness of vaccination through an 
information stand at the UMC restaurants, a 
website, a folder and plenary meetings
•	 Polls and a quiz on the intranet
•	 Video testimonials with role models
Knowledge on 
the contents 
of the Health 
Council’s 
Advice
•	 Provide and explain contents of the advice 
on the intranet or website
•	 Explain and discuss in a plenary meeting
Vaccination 
of HCWs 
to ensure 
continuity of 
care
•	 Explain and discuss ethical aspects (plenary 
meeting, website)
•	 Video testimonials with role models
•	 Involve board of directors (e.g. first 
vaccination, be present at vaccination, 
column)
•	 Distribute pins to vaccinated HCWs saying 
‘deliberately vaccinated for you’ to start the 
discussion
Vaccination of 
HCWs because 
of their duty to 
do no harm
•	 Explain and discuss ethical aspects (plenary 
meeting, website)
•	 Video testimonials with role models
•	 Involve board of directors (e.g. first 
vaccination, be present at vaccination, 
column)
•	 Distribute pins to vaccinated HCWs saying 
‘deliberately vaccinated for you’ to start the 
discussion
Belief that 
people around 
me think it 
is important 
for me to get 
vaccinated
•	 Personal invitation letter with information 
folder and a link to the website at the home 
address
Willingness to 
get vaccinated 
if the vaccine 
was available 
at a convenient 
time 
•	 Poster with practical information on location 
and time
•	 Personal invitation at home address with 
location and time
•	 Extended vaccination hours which take 
changing shifts into account
HCW: healthcare worker; UMC: University Medical Center.
4 www.eurosurveillance.org
rates for the month December were provided by each 
department of occupational health of all UMCs after 
the influenza seasons. Vaccine uptake and absentee-
ism among HCWs were both analysed at cluster level.
As further secondary outcome, patient outcome data 
from two selected high risk departments i.e. paediat-
rics and internal medicine, were collected retrospec-
tively for all patients hospitalised three days or more, 
to ensure nosocomial exposure during both study sea-
sons. In the 2009/10 influenza season, a lower number 
of patients could be included after vaccination of HCWs, 
since the campaign had begun late in the epidemic, 
whereas we could observe a high number of patients 
during the complete season of 2010/11. The outcomes 
collected were laboratory-confirmed influenza and/or 
pneumonia, length of hospital stay in days, admittance 
to intensive care and duration. They were compiled by 
scrutinising computerised discharge letters from the 
patients’ medical files and information from the micro-
biology laboratories by two reviewers. Influenza was 
defined as laboratory-confirmed influenza A (all sub-
types) or influenza B during hospital stay. Pneumonia 
was defined as any pneumonia which was clinically 
diagnosed during hospital stay. Since vaccination cov-
erage was different between departments, patient data 
were analysed at department level. Since pneumonia is 
a common complication following influenza, influenza 
remains often undiagnosed and the combined outcome 
is regarded most accurate and specific. In accordance 
with previous studies among seniors we combined this 
outcome [11].        
We were able to obtain patient outcome data on a large 
number of patients in two departments during the 
influenza seasons.   
Sample size
We aimed to include all HCWs from the eight UMCs 
prior to conducting the study. Sample size calculations 
for cluster randomised studies were applied. Based on 
the high vaccine uptake among patients (around 70%) 
we expected that we could raise the vaccine coverage 
of staff in the intervention group from 37%, the high-
est vaccination rate in all UMCs as estimated by ques-
tionnaire [17] to at least 70% and that the control group 
would remain at 37% coverage. We assumed that all 
eight UMCs would participate. A minimum of 32 par-
ticipants per UMC (128 per cluster) were needed to pro-
vide more than 80% power if the intra-class correlation 
(ICC) was estimated at 10% and significance level was 
set at 5%. Given the much higher numbers of HCWs per 
UMC, smaller effects could be detected with adequate 
power.  
Statistical methods
Data were analysed using SPSS for Windows, version 
18.0 and SAS statistical package 9.1. All outcomes 
were analysed at cluster level. In addition, patient 
outcomes were analysed at departmental level. For 
the primary outcome influenza vaccine coverage and 
absenteeism rates, we calculated risk differences (RD) 
and relative risks (RR) with their corresponding 95% 
confidence intervals (95% CI) and the levels of sta-
tistical significance in the different clusters for both 
influenza seasons combined. This was done by a spe-
cifically designed bootstrap program in R statistical 
software [20] to account for clustering. To account for 
dependencies of individual observations within hospi-
tals and possible heterogeneity between hospitals we 
addressed our research questions within the general-
ised linear mixed model framework. To estimate RR, the 
binomial distribution was used employing the logarith-
mic function as link between the mean of the response 
and the linear part of the model using SAS statistical 
package. RD were obtained using the identity link func-
tion and the normal distribution. We calculated RR and 
corresponding 95% CI as well as levels of statistical 
significance for the patient outcomes pooled over both 
years after adjustments for small baseline differences 
Table 1
Baseline characteristics of University Medical Centers, randomised controlled trial in the Netherlands, 2009 (n=8) 
Intervention UMCs  
(n=3)
Control UMCs 
(n=3)
External UMCs
(n=2)
Mean number of HCWs’ full time equivalents 8,065 5,765 6,584
Mean number of clinical admissions 34,395 28,841 25,999
Mean HCW/patient ratio 0.23 0.20 0.25
Mean percentage of HCWs older than 40 yearsa 37.8 (SD 48.6) 42.6 (SD 49.6) 42.1 (SD 49.6)
Mean percentage of female HCWsa 86.7 (SD 34.0) 75.6 (SD 43.0) 88.9 (SD 31.6)
HCW: healthcare worker; SD: standard deviation; UMC: University Medical Center. 
a  Data derived from web-based questionnaire in 2009.
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of sex (see results). We chose to pool the data to obtain 
a more precise estimate of the effect because both 
seasons were dominated by influenza A(H1N1)pdm09 
and vaccines matched the circulating strain in both 
seasons. Adjusted differences in duration of hospitali-
sation and intensive care admission between clusters 
were compared after transformation of extreme values 
to a clinically relevant maximum (30 days for hospital 
and seven days for intensive care stay). Results were 
similar as for the non-transformed values. 
Results
Baseline characteristics
 At the beginning of the measurements in 2009, the 
baseline characteristics at the level of the whole UMC 
were determined per group (Table 1). On average, the 
intervention UMCs were somewhat larger than control 
and external UMCs with more staff full time equiva-
lents and a higher number of clinical admissions each 
year. However, the mean HCW/patient ratio was com-
parable for all three groups. The age and sex distribu-
tion of staff as estimated from a web-based survey in 
2009 was similar as well (response rate 30.1%) (data 
not presented). The pooled baseline characteristics of 
patients from the selected departments of the inter-
vention and control groups showed similar mean age 
and percentage of men in the intervention and control 
group (Table 2). The percentage of patients from the 
internal medicine department and study year 2010/11 
was also similar between both groups.
Influenza vaccine uptake 
In both study seasons, influenza vaccine cover-
age among HCWs was significantly higher in the 
intervention group compared with the control group 
(Table 2). In 2009 three influenza vaccination rounds 
were offered because of the emergence of the influ-
enza A(H1N1)pdm09 pandemic virus. In all three 
groups coverage was highest for the first dose of the 
pandemic vaccine. In the intervention group the abso-
lute difference in vaccine coverage compared with the 
control group, for the first dose of the pandemic vac-
cine was 23.7% (95% CI 4.3% to 47.8%, p<0.05). For the 
second pandemic vaccine dose, coverage was lower in 
all groups than for the first one, but still 21.4% higher 
in the intervention than in the control group (95% CI: 
3.6% to 40.3%; p<0.05). The external UMCs, which 
were already more active in their vaccination campaign 
prior to the study than the randomised UMCs, reached 
even higher influenza vaccine uptake rates compared 
to the control UMCs in all vaccination rounds with an 
outstanding 44.0% absolute higher uptake of the first 
pandemic vaccine dose from 38.0% to 82.0% (95% CI: 
30.0% to 53.7%; p<0.05). In 2010/11, when the pan-
demic threat was no longer an issue, coverage of the 
seasonal influenza vaccine was much lower than the 
pandemic vaccine coverage in the year before for each 
group. The absolute RD was the intervention and exter-
nal group, respectively, compared with the control 
group (both p-levels <0.05).
To obtain more insights into exposure to different pro-
gramme methods and the vaccine uptake, we related 
the number of targeted determinants to vaccine uptake 
(Figure). There was a clear trend towards increased vac-
cine coverage if more methods were applied. There was 
a significant correlation between the number of applied 
methods and vaccine coverage for both pandemic vac-
cines (first pandemic vaccine dose Spearman r=0.79, 
Table 2
Baseline characteristics of patients in eight University Medical Centers by intervention/control and department, randomised 
controlled trial in the Netherlands, 2009–2011 (n=3,367)
Intervention 
UMCs
n=1,387
Intervention 
UMCs
Department of 
Internal Medicine
n=769/1,804
Intervention 
UMCs
Department of 
Paediatrics 
n=618/1,563
Control UMCs
n=1,980
Control UMCs
Department of 
Internal Medicine
n=1,035/1,804
Control UMCs
Department of 
Paediatrics
n=945/1,563
Baseline characteristics
Mean age 
(years)
35.3
(range 0-101,  
SD 31.0)
59.8
(range 18-101,  
SD 18.8)
4.7 
(range 0-19,  
SD 5.5)
34.1
(range 0-104,  
SD 30.4)
60.0
(range 17-104,  
SD 18.3)
5.8
(range 0-23, 
SD 5.6)
Male (%) 54.2752/1,387
51.2
394/769
57.9
358/618
51.1
1,012/1,980
50.6
524/1,035
51.6
488/945
SD: standard deviation; UMC: University Medical Center.
None of the outcomes were statistically significant.
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P=0.021; second pandemic vaccine dose Spearman 
r=0.90, P=0.003). Correlation estimates were not sig-
nificant for the seasonal vaccines (2009/10: Spearman 
r=0.41, P=0.317; 2010/11: Spearman r=0.27, P=0.51).
Absenteeism
Work absenteeism rates among HCWs were recorded 
for December 2009 and December 2010 (Table 3). For 
both seasons, absenteeism rates were 0.7% to 1.2% 
higher (absolute RD) on average in both the interven-
tion and external cluster compared with the control 
group (all p<0.05 except for comparison between exter-
nal and control UMCs in 2010 where p>0.05).
Patient outcomes
Self-reported vaccine coverage in 2009/10 and 2010/11 
influenza seasons among HCWs differed between the 
two studied departments. In 2009/10 coverage of a 
pandemic vaccine in the internal medicine and pediat-
ric departments of intervention UMCs was 100% and 
50%, and 92% and 81% in control UMCs, respectively. 
In 2010/11, corresponding vaccine coverage were 57% 
and 50%, and 51% and 44%, respectively. Over the two 
Figure
Number of targeted behavioural determinants in the influenza vaccination programme and vaccine uptake in healthcare 
workers in University Medical Centers by vaccine, randomised controlled trial in the Netherlands, 2009–2011
UMC: University Medical Center.
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Table 3
Influenza vaccine uptake rates and work absenteeism rates for the month of December among healthcare workers in eight 
University Medical Centers, randomised controlled trial in the Netherlands, 2009–2011
Intervention 
UMCs Control UMCs External UMCs
RD
Intervention 
vs Control
(95% 
Confidence 
interval)
RD
External vs 
Control
(95% 
Confidence 
interval)
Year 2009
Seasonal influenza vaccine 
uptake
32.3%
(9,022/27,900)
20.4%
(4,572/22,451)
48.7%
(8,231/16,893) 11.9%
a (7.5 – 15.5) 28.3%a (8.6 – 42.3)
Pandemic influenza vaccine 
uptake (first dose)
61.7%
(17,212/27,900)
38.0%
(8,541/22,451)
82.0%
(13,852/16,893) 23.7%
a (4.3 – 47.8) 44.0%a (30.0 – 53.7)
Pandemic influenza vaccine 
uptake (second dose)
45.8%
(12,772/27,900)
24.4%
(5,480/22,451)
56.7%
(9,582/16,893) 21.4%
a (3.6 – 40.3) 32.3%a (23.4 – 40.5)
Work absenteeism 
(December 2009)
4.6%
(1,297/27,900)
3.4%
(579/17,229)
4.1%
(701/16,893) 1.2%
a (0.9 – 1.7) 0.7%a (0.2 – 1.3)
Year 2010
Seasonal influenza vaccine 
uptake 
28.6%
(8,176/28,621)
17.8%
(4,345/24,459)
27.2%
(4,555/16,717) 10.8%
a (2.0 – 19.9) 9.4%a (1.0 – 17.2)
Work absenteeism 
(December 2010)
4.6%
(1,318/28,621)
3.9%
(745/19,267)b
4.6%
(765/16,717) 0.7%
a (0.1 – 1.3) 0.7% (-0.2 to 1.4)
RD: risk difference; UMC: University Medical Center. 
a  These results are statistically significant.
b  For this variable no data could be obtained from one control UMC.
study years, the probability of being tested for the pres-
ence of influenza virus during the influenza epidemics 
was nearly twice as high in the intervention cluster com-
pared with the control group, though not statistically 
significant (Table 4). Despite higher diagnostic testing 
rates, a diagnosis of influenza and/or pneumonia dur-
ing hospitalisation was made in half as many cases in 
the internal medicine department of intervention UMCs 
compared with the control UMCs (RR=0.5; 95% CI: 0.3-
0.9; p=0.015). Nosocomial pneumonia was reduced by 
a relative reduction of 76% (p=0.028). Other character-
istics did not significantly differ between groups and 
no statistically significant differences were observed 
in the paediatric departments.
Discussion
In a 2008 publication, Nicoll et al. stated that there is 
strong evidence for immunising HCWs against influ-
enza that take care of the elderly and the chronically ill 
in long-term care facilities. However, they did not find 
strong data on whether or not to vaccinate HCWs in 
other healthcare settings, such as hospitals [21]. 
Our study is the first hospital-based trial that showed 
that adopting a multi-faceted influenza vaccination 
programme was associated with improved vaccine 
coverage among HCWs. We also observed a lower 
risk for nosocomial influenza and/or pneumonia in 
hospitalised patients at the internal medicine depart-
ments during two consecutive influenza seasons, but 
we did not observe this effect in the studied paediatric 
departments.
It is surprising that only a small self-reported higher 
vaccine uptake in the departments of internal medi-
cine led to our observation of a 50% reduction of the 
RR in patient outcomes. There may be several expla-
nations for this finding. Actual vaccine coverage differ-
ences might have been higher than our self-reported 
estimates given that we observed an absolute higher 
difference of 23.7% (from 38.0% to 61.7%) and 11.9% 
(from 20.4% to 32.3%) respectively at group level in 
both seasons. Other explanations might be that not 
only vaccine uptake was higher in the intervention 
UMCs but that the programme led to more hygienic 
measures such as earlier diagnosis of influenza and 
isolation or better compliance with hand hygiene. This 
agrees with the fact that the number of influenza tests 
was twice higher in the intervention clusters than in 
the control clusters. Alternatively, baseline risks of 
patient outcomes might by chance have been differ-
ent between the departments. For example, we did 
not have pre-intervention patient outcome prevalences 
of nosocomial influenza for both clusters. Potential 
of confounding bias cannot be completely ruled out, 
but is unlikely given similar age and sex distributions 
between the two groups.
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Table 4
Pooled analysis of patient outcomes by department for intervention and control of eight University Medical Centers, 
randomised controlled trial in the Netherlands, 2009-2011 (n=3,367)
Intervention 
UMCs
Department 
of Internal 
Medicine
n=769/1,804
Intervention 
UMCs
Department 
of Paediatrics 
n=618/1,563
Control UMCs
Department 
of Internal 
Medicine
n=1,035/1,804
Control 
UMCs
Department 
of 
Paediatrics
n=945/1,563
RR (95% 
Confidence 
interval)
p value
Department 
of Internal 
Medicine
RR (95% 
Confidence 
interval)
p value
Department of 
Paediatrics
Outcomes
Tested for influenza during 
hospitalisation
17.6%
121/688a
10.4%
46/441a
7.2%
75/1,035
7.6%
72/945
2.1 (0.5 – 8.4)
p=0.29
2.0 (0.7 – 6.1)
p=0.22
Influenza and/or pneumonia during 
hospitalisation
3.9%
30/769
3.6%
22/618
9.7%
100/1,035
1.9%
18/945
0.47 (0.3 – 0.9)
p=0.015
2.1 (0.7 – 6.7)
p=0.19
Pneumonia during hospitalisation 1.4%11/769
1.3%
8/618
8.5%
88/1,035
1.1%
10/945
0.24 (0.1 – 0.9)
p= 0.03
1.5 (0.3 – 7.3)
p=0.65
Use of intensive care during 
hospitalisation
5.5%
42/769
8.3%
51/618
7.4%
77/1,035
8.5%
80/945
0.7 (0.4 – 1.3)
p=0.29
0.6 (0.1 – 3.5)
p=0.56
Mean duration of hospitalisation (in 
days, risk difference is given)b 10.2 (SD 8.1) 8.7 (SD 7.6) 10.7 (SD 8.4) 8.1 (SD 7.1)
0.96
(-11.82 to 13.73)
p=0.85
0.60
(-3.32 to 4.52)
p=0.69
Mean duration of intensive care use 
(in days, risk difference is given)c
3.5 (SD 2.3)
n=42
3.2 (SD 2.0)
n=51
4.4 (SD 2.5)
n=77
4.3 (SD 2.3)
n=80
-0.91
(-1.83 to 0.009)
p=0.12
-1.14
(-1.92 to -0.36)
p=0.06
RR: relative risk; SD: standard deviation; UMC: University Medical Center.
a  For this variable no data could be obtained from one intervention UMC.
b  Until 30 days.
c  Until 7 days. 
Further, vaccine uptake was measured at the level of 
the UMCs and could not be obtained from all individ-
ual departments because of the centralisation of the 
immunisation in most UMCs. Of note, at baseline prior 
to the trial start, vaccine coverage might have been 
higher in departments of intervention UMCs than in 
control UMCs. Self-reported data from HCWs showed, 
however, that the seasonal influenza vaccine cover-
age in 2008/09 was 44% and 14% among HCWs of 
the internal medicine and paediatric departments in 
intervention UMCs and 54% and 58% in control UMCs, 
respectively, hence baseline differences cannot explain 
the improved coverage. The uptake at UMC level most 
probably accurately reflects the coverage in most but 
not all departments as observed for the departments 
of paediatrics and internal medicine. The self-reported 
coverage was almost twice higher than the overall UMC 
level data because of the high-risk residents of these 
departments and longer tradition of taking hygienic 
preventive measures against infectious diseases in 
internal medicine and paediatric departments, as com-
pared with most other departments. 
The lead contacts and researchers were not blinded 
for the allocated strategy; hence this may have caused 
information bias. However, since the numbers of admin-
istered vaccines is a marker of quality of care in the 
UMCs and administration has financial consequences, 
it is highly unlikely that such bias has occurred. 
A major strength of the study includes the randomised 
design which resulted in largely comparable HCWs 
and patient populations over the study years. Also, 
the presence of a control group accounted for natural 
fluctuation in vaccine coverage as well as external fac-
tors at a national level, and the presence of an exter-
nal group confirming the positive correlation between 
a targeted campaign and influenza vaccine uptake 
among HCWs was a major strength. Moreover, the 
size of the trial HCWs population and patient popula-
tion was more than adequate to obtain highly precise 
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estimates of the main effects. Finally, in day-to-day 
practice swabbing is not routinely done and can there-
fore not have affected differentially the intervention 
and control UMCs.        
The work absenteeism rate was 1.2 HCWs per 100 
HCWs higher in the whole month of December 2009 in 
the intervention than in control clusters. Since testing 
for influenza appeared to be more frequent in interven-
tion than control UMCs, if anything, it is likely a marker 
of stricter working rules applied during influenza sea-
sons in the intervention compared with control UMCs. 
Obviously, routine swabbing of all patients suspected 
of influenza would have been the ideal study outcome. 
Because the pandemic threat was over in 2010 [22], 
the absolute risk difference for the trial population 
was down to 0.7 per 100 HCWs during the latter study 
season. One participating UMC from the control group 
could not reliably obtain absenteeism data at their UMC 
level. However, department specific data that could be 
obtained showed similar rates as within similar depart-
ments of the other control UMCs. 
The participating hospitals were tertiary centers and 
the observed effects may not necessarily be appli-
cable to all types of hospitals. In a survey among 
administrators of all hospitals in the Netherlands in 
2010 with a response rate of over 53%, we observed 
that the average vaccine coverage of staff reported 
by the administrators was comparable with the cover-
age in control UMCs (17.7% versus 17.8% in our study) 
[23]. Interestingly, in that survey we observed a clear 
association between economic spending on the immu-
nisation programme in these hospitals and vaccine 
coverage, with higher programme spending (>1,250 
Euro versus ≤1,250 euro) leading to 9% improved cov-
erage (24% versus 15%; 95% CI for the difference: 0.7% 
to 17%). We also observed in our trial that the higher 
the number of determinants targeted, the higher vac-
cine uptake in both study seasons (Figure). Although 
evidence is scarce, the introduction of a thoroughly 
developed programme likely leads to improved cover-
age in any type of hospital.       
In 2009, the influenza A(H1N1)pdm09 pandemic also 
affected the Netherlands, starting in early October 
and ending in December 2009. Following the advice 
from the World Health Organization and the Dutch 
Health Council, the Ministry of Health decided that risk 
patient groups should be prioritised for pandemic vac-
cination against this new influenza variant. HCWs were 
considered both as an important potential transmitter 
of influenza to risk patients and essential in the care of 
patients during a pandemic and were considered a tar-
get group for pandemic vaccination. As in most other 
countries, the pandemic was associated with enormous 
media attention and fear in the community. Therefore, 
in summer of 2009, all UMCs installed their pandemic 
response team and prepared for a worst case scenario 
[24]. The installed preventive measures were very 
costly, reaching hundred thousands of Euros per UMC, 
and led to pressure on both management and HCWs. It 
was therefore unexpected to see that despite general 
circumstances, both the intervention and external clus-
ter reached higher vaccine coverage than the controls. 
After the pandemic was declared over and it appeared 
to be much less severe than had initially been feared 
[24], we hypothesized that many HCWs were displeased 
about the pressure on them and the measures taken. In 
2010/11, therefore, seasonal vaccine coverage was half 
the coverage of the first dose of pandemic vaccine, and 
despite higher coverage in the intervention than the 
control cluster, it remained below a staggering low of 
30%.   
In conclusion, our results suggest that a multi-fac-
eted influenza vaccination programme for hospital 
HCWs is effective in raising vaccine uptake among 
HCWs. Although bias cannot be completely ruled out, 
an increase in vaccine coverage was associated with 
a decrease in influenza and/or pneumonia among 
patients during hospitalisation. Given the current evi-
dence for annual risks of influenza complications in 
hospital and benefits of vaccination, and the low vol-
untary coverage, mandatory programmes should be 
seriously considered.     
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